US Stock MarketDetailed Quotes

CERS Cerus

Watchlist
  • 1.670
  • +0.010+0.60%
Close Nov 21 16:00 ET
  • 1.670
  • 0.0000.00%
Post 16:01 ET
310.14MMarket Cap-15181P/E (TTM)
Post-Market
  • 5D
  • Daily
  • Weekly
  • Monthly
  • 1Q
  • 1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

Comments

    我要向钱看
    我要向钱看
    Oct 31 01:51
    $Cerus (CERS.US)$ Financial Performance:
    Cerus Corporation reported Q3 product revenue of $46 million, achieving a 16% year-over-year growth. The nine-month period product revenue summed up to $129.5 million, indicating an 18% increase from the prior year.
    Notable improvements in product gross margins which reached 56.9% in Q3, a rise of 200 basis points from the prior year's same period, attributed primarily to reduced product and supply chain costs.
    Operating expenses in Q3 amounted to $31.8...
    Jaguar8
    Jaguar8
    Oct 30 15:00
    NEWS
    $Cerus (CERS.US)$
    Third Quarter and First Nine-Month Product Revenue Increased 16% and 18%, respectively from Prior Year Periods
    Raising Full-Year 2024 Total Product Revenue Guidance to the Range of $177 million to $179 million and INTERCEPT Fibrinogen Complex Revenue Guidance to a range of $9 to $10 million
    我要向钱看
    我要向钱看
    Oct 24 21:42
    UPDATES
    $Cerus (CERS.US)$$Cerus (CERS.US)$ is scheduled to release its financial results post-market on October 30 ET.
    Earnings Preview
    Analysts estimate $Cerus (CERS.US)$ to post revenue of USD47.80M for 2024Q3, up 20.18% YOY;
    EPS is estimated to be USD-0.03, Net Loss Narrowed 18.8% YoY.
    The accounting standard used for the above data is US-GAAP.
    我要向钱看
    我要向钱看
    Oct 16 22:06
    $5 TP
    $Cerus (CERS.US)$ TD Cowen analyst Josh Jennings maintains $Cerus (CERS.US)$ with a buy rating, and maintains the target price at $5.
    Jaguar8
    Jaguar8
    Oct 16 15:01
    NEWS
    $Cerus (CERS.US)$
    Cerus Corporation Provides Updates on INTERCEPT Red Blood Cell Programs in the U.S. and Europe
    Cerus (Nasdaq:CERS) has provided updates on its INTERCEPT red blood cell (RBC) programs in the U.S. and Europe. In the U.S., Cerus has secured a new $248 million contract with BARDA to support the program through FDA approval and commercialization. The company recently announced positive topline results for the ReCePI study, a pivotal U.S. Phase 3 clinical trial.
    In Europe, the CE ...
Read more

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
US
Overall
Symbol
Latest Price
% Chg

No Data